Novo Nordisk plunks down $2.6B to ramp up production in Denmark

Dec. 13, 2021

Novo Nordisk unveiled plans to invest $2.58 billion into increasing production capacity across the pharma value chain at its production site in Kalundborg, Denmark.

Diabetes drugmaker will construct three new manufacturing facilities as well as expand an existing facility in a bid to ensure future production capacity for its oral and injectable product portfolio.

While vast majority of the investment will be used to build API capacity, the construction will also expand assembly and packaging. According to Novo, the new facilities will be automated and include state-of-the-art production technologies.

The drugmaker says investment projects are expected to be finalized in 2027 and will create around 400 new jobs, as well as engage 2,500 external staff in the building phase. ​